Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

EXOZ

eXoZymes Inc

4.80

Aug 04 • 2:46 PM ET +0.20 (4.35%)

Healthcare Biotechnology USA Nano NASD

Peers: ANIX ATYR COYA CYPH FBIO INO LONA NRXS NRXP KALA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	44.55M
Enterprise Value	44.27M
Income	-9.67M
Sales	0.00M
Book/sh	0.18
Cash/sh	0.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	32
IPO	Nov 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	26.63
P/C	30.93
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.32
Current Ratio	1.32
Debt/Eq	0.76
LT Debt/Eq	0.54
Option/Short	No / Yes

EPS (ttm)	-1.15
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-87.11% -74.96%
Sales past 3/5Y	- -
EPS Y/Y TTM	-32.48%
Sales Y/Y TTM	-
EPS Q/Q	-26.33%
Sales Q/Q	-
Earnings	Mar 31 AMC
EPS/Sales Surpr.	- -

Insider Own	68.54%
Insider Trans	-0.02%
Inst Own	0.95%
Inst Trans	0.27%
ROA	-124.45%
ROE	-185.84%
ROIC	-410.19%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.35%
SMA50	-33.94%
SMA200	-52.73%
Trades

Shs Outstand	8.48M
Shs Float	2.92M
Short Float	0.67%
Short Ratio	2.20
Short Interest	0.02M
52W High	18.40 -73.91%
52W Low	4.35 10.34%
Volatility	7.30% 10.53%
ATR (14)	0.58
RSI (14)	32.88
Beta	2.92
Rel Volume	0.37
Avg Volume	8.89K
Volume	2,691

Perf Week	9.09%
Perf Month	-41.03%
Perf Quarter	-51.61%
Perf Half Y	-54.97%
Perf YTD	-55.96%
Perf Year	-51.71%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	4.60
Price	4.80
Change	4.35%

Jul-23-26 04:15PM	eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing (ACCESSWIRE) -8.38%
Jun-24-26 04:10PM	eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery (ACCESSWIRE) -7.27%
Jun-17-26 04:10PM	eXoZymes Inc. Announces Closing of $6 Million Public Offering (ACCESSWIRE) -14.69% +23.70%
Jun-08-26 09:00AM	eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants (ACCESSWIRE) -7.71%
May-07-26 09:05AM	eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program (ACCESSWIRE) -5.12%
09:10AM	Loading…
Apr-10-26 09:10AM	eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast (ACCESSWIRE)
Apr-06-26 09:00PM	MDB Capital Holdings LLC (MDBH) Q4 2025 Earnings Call Highlights: Strategic Innovations and ... (GuruFocus.com) +14.99%
Mar-31-26 11:02PM	EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) +12.38%
04:20PM	eXoZymes Provides Fourth Quarter and Full Year 2025 Update (ACCESSWIRE)
Mar-25-26 04:10PM	eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 (ACCESSWIRE)
Mar-18-26 09:10AM	Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability (ACCESSWIRE)
Mar-12-26 04:15PM	eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium (ACCESSWIRE)
Feb-10-26 04:20PM	With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation (ACCESSWIRE)
Jan-29-26 07:45PM	eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run (ACCESSWIRE)
Dec-11-25 04:10PM	eXoZymes Achieves 100x Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion (ACCESSWIRE) -9.81%
12:07AM	Loading…
Nov-14-25 12:07AM	EXoZymes Inc (EXOZ) Q3 2025 Earnings Call Highlights: Unlocking Market Opportunities Amid ... (GuruFocus.com) -6.95%
Nov-13-25 04:30PM	eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today (ACCESSWIRE)
04:15PM	eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff (ACCESSWIRE)
Nov-10-25 05:00PM	eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST (ACCESSWIRE) +14.29% -5.12%
Oct-30-25 04:10PM	CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference (ACCESSWIRE)
Oct-29-25 05:40PM	CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference (ACCESSWIRE) +13.87%
Oct-23-25 04:50PM	CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference (ACCESSWIRE)
Oct-14-25 06:58PM	eXoZymes Inc. Partners With B2i Digital to Spotlight the Cell-Free Next Generation of Biomanufacturing (NewMediaWire)
Sep-30-25 04:10PM	Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees (ACCESSWIRE)
Aug-12-25 04:50PM	eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today (ACCESSWIRE)
Aug-07-25 06:35PM	eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST (ACCESSWIRE)
Jul-29-25 07:57AM	eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity (ACCESSWIRE)
Jul-22-25 04:10PM	eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months (ACCESSWIRE)
Jun-26-25 04:10PM	eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing (ACCESSWIRE) -5.03% +6.83%
May-16-25 09:25AM	eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast (ACCESSWIRE) +10.96%
04:10PM	Loading…
May-12-25 04:10PM	eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today (ACCESSWIRE) +16.03%
May-07-25 05:20PM	eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST (ACCESSWIRE) +13.73%
May-06-25 04:10PM	eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health (ACCESSWIRE)
Apr-21-25 04:10PM	Bringing clarity and precision to the cell-free space by introducing exozymes (GlobeNewswire) +12.61%
Apr-10-25 04:30PM	BioClick an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant (GlobeNewswire) -7.39%
Apr-02-25 04:10PM	eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO (GlobeNewswire)
04:05PM	eXoZymes Provides Fourth Quarter and Full Year 2024 Update (GlobeNewswire)
Mar-26-25 05:00PM	eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 (GlobeNewswire) -19.67%
Mar-03-25 08:40PM	New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce (ACCESS Newswire)
Feb-21-25 04:05PM	eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. (GlobeNewswire)
Feb-19-25 08:25AM	eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering (GlobeNewswire)
Feb-10-25 11:00AM	Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol (GlobeNewswire)
Nov-19-24 09:05AM	Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities (GlobeNewswire) +14.54%
Nov-14-24 04:05PM	Invizyne Technologies Announces Closing of Initial Public Offering (GlobeNewswire) +19.77% +7.34%
Nov-13-24 04:05PM	Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing (GlobeNewswire)
09:05AM	Invizyne Technologies Begins Trading on NASDAQ (GlobeNewswire)
Nov-12-24 10:52AM	Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024 (GlobeNewswire)

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

President & CEOMr. Michael Heltzen

Co-Founder & Chief Scientific OfficerDr. Tyler Korman Ph.D.

Co-Founder & Vice President of DevelopmentDr. Paul Opgenorth Ph.D.

Founder & Independent DirectorMr. James U. Bowie Ph.D.

Vice President of FinanceMr. Fouad Nawaz

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Korman Tyler Paz	Chief Scientific Officer	Apr 09 '26	Sale	10.53	750	7,894	729,123	Apr 10 04:30 PM
Korman Tyler Paz	Chief Scientific Officer	Apr 08 '26	Sale	10.04	750	7,530	729,873	Apr 10 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EXOZ

eXoZymes Inc

Upgrade your Finviz experience